Indaptus Therapeutics is trading at $1.52 (+14.29%) in pre-market sessions despite a lack of identifiable company-specific catalysts in current news flow.
- The significant price move is likely being driven by speculative trading in the thinly traded small-cap name rather than a confirmed corporate announcement.
- Broader U.S. equity futures remain mixed with soft sentiment in the tech sector, suggesting the move is not tied to a wider market-wide risk-on trend.